Jason H. Rogers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jason H. Rogers has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Thomas W. Smith
Division of Cardiovascular Medicine, University of California, Davis Medical Center, Sacramento, California
15 shared publications - Gagan D. Singh
University of California Davis Medical Center, Sacramento, California, USA
14 shared publications Steven F. Bolling
10 shared publicationsWalter D. Boyd
9 shared publicationsDali Fan
8 shared publicationsGagan D. Singh
Division of Cardiovascular Medicine, University of California - Davis, Sacramento, California, USA
7 shared publications
Latest Publications
- Open Access
- 7 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (7) , e044794
Clinical, Functional, and Quality‐of‐Life Outcomes After Contemporary Transcatheter Edge‐to‐Edge Repair for Primary Mitral Regurgitation in the Very Elderly
Background: Advanced age may influence the benefits derived from transcatheter edge‐to‐edge repair for primary mitral regurgitation (MR). We explored the impact of age on clinical, echocardiographic, functional, and patient‐reported outcomes after contemporary mitral transcatheter edge‐to‐edge repair. Methods: Patients with primary MR were identified from a pooled, patient‐level analysis of the EXPAND and EXPAND G4 studies. Key outcomes included 30‐day and 1‐year major adverse events, MR severity, New York Heart Association class, Kansas City Cardiomyopathy Questionnaire – Overall Summary score, and mortality. Results: A total of 854 patients were included. The oldest quartile ranged in age from 86 to 99 years, while the younger quartiles ranged from 21 to 85 years. The 30‐day major adverse events rate was not different in the oldest compared with the younger quartiles (5.7% versus 4.3%, P =0.46). At 1 year, MR ≤1+ was present in 81% of the oldest versus 88% of the younger patients ( P =0.08). LV end‐diastolic volumes improved to similar extent (−12.0±28.8 mL, P =0.003 and −14.1±31.5 mL, P P =0.34 across groups). Functional status and Kansas City Cardiomyopathy Questionnaire – Overall Score improved significantly across age groups, without differences according to age. Adjusted 1‐year mortality was higher in the oldest compared with the younger quartiles (adjusted hazard ratio 1.74 [95% CI, 1.02–2.98], P =0.04). Conclusions: Although 1‐year mortality was higher among the very elderly, mitral transcatheter edge‐to‐edge repair using next‐generation devices was associated with low complication rates and substantial improvements in ventricular remodeling, functional status, and quality of life across age groups. These findings support the use of mitral transcatheter edge‐to‐edge repair in appropriately selected elderly patients and suggest that age alone should not be a barrier to treatment.
- 7 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (7) , e044794
Open AccessClinical, Functional, and Quality‐of‐Life Outcomes After Contemporary Transcatheter Edge‐to‐Edge Repair for Primary Mitral Regurgitation in the Very Elderly
Background: Advanced age may influence the benefits derived from transcatheter edge‐to‐edge repair for primary mitral regurgitation (MR). We explored the impact of age on clinical, echocardiographic, functional, and patient‐reported outcomes after contemporary mitral transcatheter edge‐to‐edge repair. Methods: Patients with primary MR were identified from a pooled, patient‐level analysis of the EXPAND and EXPAND G4 studies. Key outcomes included 30‐day and 1‐year major adverse events, MR severity, New York Heart Association class, Kansas City Cardiomyopathy Questionnaire – Overall Summary score, and mortality. Results: A total of 854 patients were included. The oldest quartile ranged in age from 86 to 99 years, while the younger quartiles ranged from 21 to 85 years. The 30‐day major adverse events rate was not different in the oldest compared with the younger quartiles (5.7% versus 4.3%, P =0.46). At 1 year, MR ≤1+ was present in 81% of the oldest versus 88% of the younger patients ( P =0.08). LV end‐diastolic volumes improved to similar extent (−12.0±28.8 mL, P =0.003 and −14.1±31.5 mL, P P =0.34 across groups). Functional status and Kansas City Cardiomyopathy Questionnaire – Overall Score improved significantly across age groups, without differences according to age. Adjusted 1‐year mortality was higher in the oldest compared with the younger quartiles (adjusted hazard ratio 1.74 [95% CI, 1.02–2.98], P =0.04). Conclusions: Although 1‐year mortality was higher among the very elderly, mitral transcatheter edge‐to‐edge repair using next‐generation devices was associated with low complication rates and substantial improvements in ventricular remodeling, functional status, and quality of life across age groups. These findings support the use of mitral transcatheter edge‐to‐edge repair in appropriately selected elderly patients and suggest that age alone should not be a barrier to treatment.
- Open Access
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (2) , e015883
Atrial Secondary Mitral Regurgitation Outcomes Following Mitral Transcatheter Edge-to-Edge Repair: Results From the EXPANDed Studies
BACKGROUND: Atrial secondary mitral regurgitation (aSMR) is a distinct subtype of SMR characterized by normal leaflets, annular dilatation, left atrial (LA) enlargement, and preserved left ventricular function. Treatment pathways for aSMR are undefined, and limited data exist regarding outcomes following mitral transcatheter edge-to-edge repair (MTEER). The analysis aimed to evaluate outcomes in patients with aSMR treated with MTEER from the EXPANDed (Evaluation of the MitraClip X System Post-MArket Real-World CliNical Outcomes Database ) studies. METHODS: One-year outcomes were assessed in patients from the EXPANDed studies (EXPAND and EXPAND G4 [Evaluation of the MitraClip X System Post-MArket Real-World CliNical Outcomes Database Generation 4 ]) who met criteria for aSMR. aSMR was defined by the presence of atrial fibrillation, left ventricular ejection fraction ≥45%, and at least 1 dilated LA parameter per echocardiographic core laboratory assessment: LA volume index, LA diameter, or LA diameter index. RESULTS: Of the 967 patients with SMR treated with MTEER in the EXPANDed data set, 160 (17%) met criteria for aSMR. Patients with aSMR were elderly (78±8 years), symptomatic (Kansas City Cardiomyopathy Questionnaire Overall Summary score, 48±27 pts), and had small left ventricular and large LA dimensions at baseline. Acute procedural success was achieved in 97.5% of patients with aSMR, with MR reduction to ≤1+ in 95.2% at 1 year. There were significant 1-year improvements in quality of life (+19 pt Kansas City Cardiomyopathy Questionnaire Overall Summary) and functional capacity (New York Heart Association I/II 80%). The 1-year all-cause mortality rate was 9%, with patients experiencing a 56% reduction in 1-year heart failure hospitalization rates from pre- to post-MTEER. CONCLUSIONS: In the largest population of patients with aSMR assessed by an echocardiographic core laboratory, MTEER safely and significantly reduced MR with improvements in quality of life and reduction in heart failure hospitalization through 1 year.
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (2) , e015883
Open AccessAtrial Secondary Mitral Regurgitation Outcomes Following Mitral Transcatheter Edge-to-Edge Repair: Results From the EXPANDed Studies
BACKGROUND: Atrial secondary mitral regurgitation (aSMR) is a distinct subtype of SMR characterized by normal leaflets, annular dilatation, left atrial (LA) enlargement, and preserved left ventricular function. Treatment pathways for aSMR are undefined, and limited data exist regarding outcomes following mitral transcatheter edge-to-edge repair (MTEER). The analysis aimed to evaluate outcomes in patients with aSMR treated with MTEER from the EXPANDed (Evaluation of the MitraClip X System Post-MArket Real-World CliNical Outcomes Database ) studies. METHODS: One-year outcomes were assessed in patients from the EXPANDed studies (EXPAND and EXPAND G4 [Evaluation of the MitraClip X System Post-MArket Real-World CliNical Outcomes Database Generation 4 ]) who met criteria for aSMR. aSMR was defined by the presence of atrial fibrillation, left ventricular ejection fraction ≥45%, and at least 1 dilated LA parameter per echocardiographic core laboratory assessment: LA volume index, LA diameter, or LA diameter index. RESULTS: Of the 967 patients with SMR treated with MTEER in the EXPANDed data set, 160 (17%) met criteria for aSMR. Patients with aSMR were elderly (78±8 years), symptomatic (Kansas City Cardiomyopathy Questionnaire Overall Summary score, 48±27 pts), and had small left ventricular and large LA dimensions at baseline. Acute procedural success was achieved in 97.5% of patients with aSMR, with MR reduction to ≤1+ in 95.2% at 1 year. There were significant 1-year improvements in quality of life (+19 pt Kansas City Cardiomyopathy Questionnaire Overall Summary) and functional capacity (New York Heart Association I/II 80%). The 1-year all-cause mortality rate was 9%, with patients experiencing a 56% reduction in 1-year heart failure hospitalization rates from pre- to post-MTEER. CONCLUSIONS: In the largest population of patients with aSMR assessed by an echocardiographic core laboratory, MTEER safely and significantly reduced MR with improvements in quality of life and reduction in heart failure hospitalization through 1 year.
- Open Access
- 25 October 2025
- Published by Elsevier in Structural Heart
- Vol. 9 (12) , 100743
Impact of Central vs. Noncentral Predominant Jet Location on Clinical Outcomes: Results From the EXPANDed Studies
- 25 October 2025
- Published by Elsevier in Structural Heart
- Vol. 9 (12) , 100743
Open AccessImpact of Central vs. Noncentral Predominant Jet Location on Clinical Outcomes: Results From the EXPANDed Studies
- 23 September 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (18) , 2267-2269
Transcatheter Mitral Valve Replacement
- 23 September 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (18) , 2267-2269
Transcatheter Mitral Valve Replacement
- Open Access
- 21 March 2025
- Published by Elsevier in Structural Heart
- Vol. 9 (6)
Impact of Baseline Anteroposterior Mitral Annular Dimensions on Clinical Outcomes after MitraClip for Secondary Mitral Regurgitation
- 21 March 2025
- Published by Elsevier in Structural Heart
- Vol. 9 (6)
Open AccessImpact of Baseline Anteroposterior Mitral Annular Dimensions on Clinical Outcomes after MitraClip for Secondary Mitral Regurgitation
- Open Access
- 1 January 2024
- Published by Fortune Journals in Cardiology and Cardiovascular Medicine
- Vol. 08 (01) , 7-14
Triple versus Double Orifice Valves After Transcatheter Edge-to-Edge Repair: Clinical Features and Outcomes
Rationale: Procedural and clinical outcomes of triple orifice valves created by mitral valve transcatheter edge-to-edge repair (TEER) have not been previously characterized. Methods: 201 patients undergoing MitraClip were retrospectively analyzed from 2014-2019 (before generation 4 MitraClip release). A triple orifice valve was defined as having three orifices with all diastolic inflow diameters > 4 mm (the width of a non-XTW/NTW MitraClip). We reviewed pre- and post-procedure pressure gradients, hemodynamic parameters, and mitral regurgitation (MR) grades in triple vs. double orifice valves. Results: Patients with triple orifice valves after MitraClip (n=13) had lower baseline mean pressure gradients across the mitral valve compared to double orifice valves, although this difference was not significant (1.4 ± 0.8 vs 1.8 ±.2 mmHg, p = 0.15). They also did not have significantly different post-procedure gradients (5.0 ± 2.8 vs 4.6 ±2.2 mmHg, p = 0.59). MR grade pre- and post-TEER was similar between the two groups. Procedural hemodynamic parameters were also similar between the two groups. Conclusions: In this single center retrospective study, we found that the creation of a triple orifice mitral valve after MitraClip had a comparable impact on the final gradients when compared to double orifice, perhaps due to lower baseline gradients. Overall MR reduction was similar. The need to create triple orifice valves in selected patients is often driven by more complex baseline disease with multiple or wide jets.
- 1 January 2024
- Published by Fortune Journals in Cardiology and Cardiovascular Medicine
- Vol. 08 (01) , 7-14
Open AccessTriple versus Double Orifice Valves After Transcatheter Edge-to-Edge Repair: Clinical Features and Outcomes
Rationale: Procedural and clinical outcomes of triple orifice valves created by mitral valve transcatheter edge-to-edge repair (TEER) have not been previously characterized. Methods: 201 patients undergoing MitraClip were retrospectively analyzed from 2014-2019 (before generation 4 MitraClip release). A triple orifice valve was defined as having three orifices with all diastolic inflow diameters > 4 mm (the width of a non-XTW/NTW MitraClip). We reviewed pre- and post-procedure pressure gradients, hemodynamic parameters, and mitral regurgitation (MR) grades in triple vs. double orifice valves. Results: Patients with triple orifice valves after MitraClip (n=13) had lower baseline mean pressure gradients across the mitral valve compared to double orifice valves, although this difference was not significant (1.4 ± 0.8 vs 1.8 ±.2 mmHg, p = 0.15). They also did not have significantly different post-procedure gradients (5.0 ± 2.8 vs 4.6 ±2.2 mmHg, p = 0.59). MR grade pre- and post-TEER was similar between the two groups. Procedural hemodynamic parameters were also similar between the two groups. Conclusions: In this single center retrospective study, we found that the creation of a triple orifice mitral valve after MitraClip had a comparable impact on the final gradients when compared to double orifice, perhaps due to lower baseline gradients. Overall MR reduction was similar. The need to create triple orifice valves in selected patients is often driven by more complex baseline disease with multiple or wide jets.
- 26 October 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (23) , 2817-2819
Head-to-Head Transcatheter Mitral Edge-to-Edge Repair
- 26 October 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (23) , 2817-2819
Head-to-Head Transcatheter Mitral Edge-to-Edge Repair
- Open Access
- 26 June 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (12) , 1474-1485
Expanding the Spectrum of TEER Suitability
- 26 June 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (12) , 1474-1485
Open AccessExpanding the Spectrum of TEER Suitability
- 7 June 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (11) , 1347-1357
Transcatheter Left Atrial Appendage Exclusion
- 7 June 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (11) , 1347-1357
Transcatheter Left Atrial Appendage Exclusion